{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:18Z","timestamp":1788883698207,"version":"build-2803163510"},"reference-count":58,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We report a phase 1 study assessing the safety and efficacy of CD19 chimeric antigen receptor (CAR) T cells as definitive consolidation in older adults (aged \u226555 years) with B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission (CR1). Eighteen patients received lymphodepletion followed by infusion of memory-enriched CD19 CAR T cells. The median age was 64 years, and all patients were measurable residual disease (MRD)\u2013negative before lymphodepletion. There were no dose-limiting toxicities, grade \u22652 cytokine release syndrome, or any grade immune effector cell\u2013associated neurotoxicity syndrome. Estimated 18-month event-free and overall survival were 84% and 100%, respectively. CAR T cells expanded in the blood and cerebrospinal fluid despite patients\u2019 MRD-negative status. Comparing clinical samples from patients with relapsed\/refractory (R\/R) B-ALL from our historical trial (ClinicalTrials.gov identifier: NCT02146924) and patients in CR1, we found that the blood and CAR T-cell products from patients with R\/R B-ALL were hyperinflammatory and hyperimmunometabolic, respectively. First-line CAR T-cell therapy was safe and well tolerated and potentially extended remission in patients in MRD-negative CR1. These findings support further investigation of the early use of CAR T-cell therapy for B-ALL. This trial was registered at www.clinicaltrials.gov as NCT05707273.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020963","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:04:53Z","timestamp":1782335093000},"page":"5874-5885","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission"],"prefix":"10.1182","volume":"10","author":[{"given":"Ibrahim","family":"Aldoss","sequence":"first","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-7616","authenticated-orcid":false,"given":"Lior","family":"Goldberg","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"3Department of Pediatrics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Computational and Quantitative Sciences, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-2684","authenticated-orcid":false,"given":"Mary C.","family":"Clark","sequence":"additional","affiliation":[{"name":"5Department of Clinical and Translational Project Development, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Guan","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Espinosa","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-8058","authenticated-orcid":false,"given":"Thiruvaimozhi","family":"Abimannan","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wu","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Garcia","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-9331","authenticated-orcid":false,"given":"Eric R.","family":"Haas","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khyatiben V.","family":"Pathak","sequence":"additional","affiliation":[{"name":"6Integrated Mass Spectrometry Shared Resource, City of Hope, Duarte, CA"},{"name":"7Early Detection and Prevention Division, The Translational Genomics Research Institute, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1023-2186","authenticated-orcid":false,"given":"Brooke","family":"Lovell","sequence":"additional","affiliation":[{"name":"6Integrated Mass Spectrometry Shared Resource, City of Hope, Duarte, CA"},{"name":"7Early Detection and Prevention Division, The Translational Genomics Research Institute, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-6039","authenticated-orcid":false,"given":"Patrick","family":"Pirrotte","sequence":"additional","affiliation":[{"name":"6Integrated Mass Spectrometry Shared Resource, City of Hope, Duarte, CA"},{"name":"7Early Detection and Prevention Division, The Translational Genomics Research Institute, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Agrawal","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neguine","family":"Sanani","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kasten","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileshni","family":"Tilakawardane","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie R.","family":"Wagner","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinny","family":"Paul","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6998-6643","authenticated-orcid":false,"given":"Haoyue","family":"Shan","sequence":"additional","affiliation":[{"name":"4Department of Computational and Quantitative Sciences, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Khaled","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-5320","authenticated-orcid":false,"given":"Paul","family":"Koller","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"},{"name":"2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"6","key":"2026090811315492400_bib1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"13","key":"2026090811315492400_bib2","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2026090811315492400_bib3","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"2026090811315492400_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J Clin Oncol"},{"issue":"36","key":"2026090811315492400_bib5","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026090811315492400_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","article-title":"Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia","volume":"9","author":"Luskin","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026090811315492400_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2026090811315492400_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/JOP.18.00271","article-title":"Acute lymphoblastic leukemia in the older adult","volume":"15","author":"Aldoss","year":"2019","journal-title":"J Oncol Pract"},{"issue":"1","key":"2026090811315492400_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.24575","article-title":"Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia","volume":"92","author":"Rosko","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2026090811315492400_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"23","key":"2026090811315492400_bib11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"2026090811315492400_bib12","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026090811315492400_bib13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2026090811315492400_bib14","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026090811315492400_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2026090811315492400_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026090811315492400_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2026090811315492400_bib18","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"2026090811315492400_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"2026090811315492400_bib20","author":"Stewart","year":"1992"},{"issue":"1","key":"2026090811315492400_bib21","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41467-022-29383-5","article-title":"cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies","volume":"13","author":"Pedersen","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2026090811315492400_bib22","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1038\/s41467-023-41167-z","article-title":"Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"2026090811315492400_bib23","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.analchem.8b05592","article-title":"Systematic error removal using random forest for normalizing large-scale untargeted lipidomics data","volume":"91","author":"Fan","year":"2019","journal-title":"Anal Chem"},{"issue":"suppl 1","key":"2026090811315492400_bib24","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/bioinformatics\/18.suppl_1.S96","article-title":"Variance stabilization applied to microarray data calibration and to the quantification of differential expression","volume":"18","author":"Huber","year":"2002","journal-title":"Bioinformatics"},{"issue":"4","key":"2026090811315492400_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"issue":"3","key":"2026090811315492400_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41423-022-00840-x","article-title":"Immunometabolism at the intersection of metabolic signaling, cell fate, and systems immunology","volume":"19","author":"Chi","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"2026090811315492400_bib27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/0008-5472.CAN-23-2299","article-title":"Immunometabolic adaptation of CD19-targeted CAR T cells in the central nervous system microenvironment of patients promotes memory development","volume":"84","author":"Goldberg","year":"2024","journal-title":"Cancer Res"},{"issue":"32","key":"2026090811315492400_bib28","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1200\/JCO-25-00307","article-title":"Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed B-cell ALL: alliance study A041703 cohort 1 results","volume":"43","author":"Wieduwilt","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026090811315492400_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1182\/blood-2025-442","article-title":"Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: a prospective phase 2 study","volume":"146","author":"Gu","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026090811315492400_bib30","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood-2025-1561","article-title":"Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: results from a prospective, phase 2 study","volume":"146","author":"Gu","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026090811315492400_bib31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"100","author":"Brissot","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2026090811315492400_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026090811315492400_bib33","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Foa","year":"2023","journal-title":"J Clin Oncol"},{"issue":"36","key":"2026090811315492400_bib34","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026090811315492400_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cncr.33967","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"2026090811315492400_bib36","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"issue":"19","key":"2026090811315492400_bib37","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2026090811315492400_bib38","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2026090811315492400_bib39","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026090811315492400_bib40","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jtct.2025.05.003","article-title":"Low peripheral blood counts and elevated proinflammatory cytokines signal a poor CD19 chimeric antigen receptor T-cell response in acute lymphoblastic leukemia","volume":"31","author":"Burleigh","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"2026090811315492400_bib41","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2026090811315492400_bib42","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/2159-8290.CD-22-1175","article-title":"Type I interferon signaling via the EGR2 transcriptional regulator potentiates CAR T cell-intrinsic dysfunction","volume":"13","author":"Jung","year":"2023","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2026090811315492400_bib43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2021-148013","article-title":"Poor clinical outcome in pediatric immunotherapy is mediated by a pre-existing overactive IL-18-IFNy immune phenotype","volume":"138","author":"Burleigh","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2026090811315492400_bib44","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026090811315492400_bib45","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"2026090811315492400_bib46","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026090811315492400_bib47","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2024-197968","article-title":"Type I interferon impairs the function of CAR-T cells by disrupting immune synapse assembly","volume":"144","author":"Huang","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026090811315492400_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41467-023-35948-9","article-title":"IFN\u03b3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells","volume":"14","author":"Mazet","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2026090811315492400_bib49","doi-asserted-by":"crossref","first-page":"e05209","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Mart\u00edn-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"issue":"2","key":"2026090811315492400_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2026090811315492400_bib51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026090811315492400_bib52","first-page":"S239","article-title":"Emapalumab for the treatment of toxicities associated with CD19 CAR-T cells in adult patients","volume":"31","author":"Johnson","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026090811315492400_bib53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity"},{"issue":"23","key":"2026090811315492400_bib54","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1016\/j.cell.2024.08.029","article-title":"Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy","volume":"187","author":"Baldwin","year":"2024","journal-title":"Cell"},{"issue":"3","key":"2026090811315492400_bib55","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","article-title":"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma","volume":"31","author":"Quintarelli","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"2026090811315492400_bib56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.18816","article-title":"Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"202","author":"Dubnikov Sharon","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"2026090811315492400_bib57","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41467-026-69857-4","article-title":"Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy","volume":"17","author":"Goldberg","year":"2026","journal-title":"Nat Commun"},{"issue":"18","key":"2026090811315492400_bib58","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1182\/bloodadvances.2023009976","article-title":"Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5874\/2541758\/blooda_adv-2026-020963-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5874\/2541758\/blooda_adv-2026-020963-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:03Z","timestamp":1788881523000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5874\/569361\/CAR-T-cell-therapy-as-a-definitive-consolidation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":58,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020963","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}